Abstract
Cell and gene therapies have emerged as promising treatments for previously untreatable diseases, with viral vectors being used as the current preferred delivery vehicle. Safe, robust, and cost-effective vector manufacturing processes are necessary to support the demands of the patient population. Here, expert therapy developers, solutions providers, and CDMOs discuss considerations for the successful scale-up of viral vector processes from bench to commercial manufacturing.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have